Want to see INTS full AI Analyst Report?
INTS Stock Chart & Stats
$4.45
$0.12(2.70%)
At close: 4:00 PM EDT
$4.45
$0.12(2.70%)
Day’s Range― - ―
52-Week Range$3.51 - $43.50
Previous Close$4.56
Volume10.77K
Average Volume (3M)51.49K
Market Cap
$13.06M
Enterprise Value$1.66
Total Cash (Recent Filing)$9.53M
Total Debt (Recent Filing)$95.00K
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Nov 17, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.83
Shares Outstanding3,264,879
10 Day Avg. Volume22,859
30 Day Avg. Volume51,488
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)11.72
Price to Sales (P/S)0.00
P/FCF Ratio-15.07
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.00Price Target Upside237.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.69
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy From Phase 1/2 DataPhase 1/2 publication reports INT230-6 achieved a median overall survival of 11.9 months and a 75% disease control rate in a 64-patient study, indicating efficacy above historical benchmarks for similar early‑stage cancer trials.
Financial RunwayManagement indicates cash runway through the end of the first quarter of 2027 following a $5.7 million financing, which reduces near-term funding pressure and supports continued INT230-6 development.
Sarcoma Program AdvancementIntensity Therapeutics initiated a Phase 3 study in sarcoma after observing a 21.3-month median overall survival in the metastatic sarcoma subset, creating a clearer path toward registration-directed data for that indication.
Bears Say
Development Timeline And Cost RiskEnrollment pause in INVINCIBLE-4 may delay trial progress and data readouts, potentially increasing development costs and extending the timeline to regulatory milestones.
Safety Signal In Ongoing StudyNew patient enrollment in the Phase 2 INVINCIBLE-4 study was paused due to localized skin irritation near tumor sites, creating a safety concern that could attract regulatory scrutiny.
Intensity Therapeutics, Inc. News
INTS FAQ
What was Intensity Therapeutics, Inc.’s price range in the past 12 months?
Intensity Therapeutics, Inc. lowest stock price was $3.51 and its highest was $43.50 in the past 12 months.
What is Intensity Therapeutics, Inc.’s market cap?
Intensity Therapeutics, Inc.’s market cap is $13.06M.
When is Intensity Therapeutics, Inc.’s upcoming earnings report date?
Intensity Therapeutics, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 93 days.
How were Intensity Therapeutics, Inc.’s earnings last quarter?
Intensity Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$1.11 earnings per share for the quarter, missing the consensus estimate of -$0.872 by -$0.238.
Is Intensity Therapeutics, Inc. overvalued?
According to Wall Street analysts Intensity Therapeutics, Inc.’s price is currently Undervalued.
Does Intensity Therapeutics, Inc. pay dividends?
Intensity Therapeutics, Inc. does not currently pay dividends.
What is Intensity Therapeutics, Inc.’s EPS estimate?
Intensity Therapeutics, Inc.’s EPS estimate is -0.96.
How many shares outstanding does Intensity Therapeutics, Inc. have?
Intensity Therapeutics, Inc. has 3,264,879 shares outstanding.
What happened to Intensity Therapeutics, Inc.’s price movement after its last earnings report?
Intensity Therapeutics, Inc. reported an EPS of -$1.11 in its last earnings report, missing expectations of -$0.872. Following the earnings report the stock price went down -2.098%.
Which hedge fund is a major shareholder of Intensity Therapeutics, Inc.?
Currently, no hedge funds are holding shares in INTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
INTS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated meaningful operational and scientific progress — resumption of two clinical programs, protocol amendments, encouraging early efficacy signals (notably a 71% vs 42% pCR in a small INVINCIBLE-4 cohort), and a high-impact peer-reviewed publication — alongside active business development engagement. However, substantial funding needs (estimated ~$30M to complete the Phase III), a widening quarterly net loss (+19%), prior enrollment/statistical uncertainties, and recent safety-driven pauses temper the outlook. Progress is tangible but contingent on additional capital or partnerships to fully realize the programs.View all INTS earnings summariesINTS Stock 12 Month Forecast
Average Price Target
$15.00
▲(237.08% Upside)
Technical Analysis
Cellectar Biosciences
―
PDS Biotechnology
―
GT Biopharma
―
Celularity
―
Senti Biosciences
―
Ownership Overview
3.92% Insiders
1.03% Mutual Funds
18.69% Other Institutional Investors
75.54% Public Companies and
Individual Investors